A bracelet-like device with magnetic beads can help patients with the chronic digestive disorder gastroesophageal reflux disease, according to a study.
The device encircles the valve at the junction of the esophagus and stomach and helps it stay closed when a person is not eating or drinking.
It eased symptoms in 92 of 100 patients with chronic acid reflux and allowed 87 percent of patients to stop using acid-suppressing drugs, third-year results from the five-year study showed. Ninety four percent of patients were satisfied with the treatment.
The advance is significant, says study co-author C. Daniel Smith, M.D., chair of the Surgery Department at Mayo Clinic in Florida and a specialist in treating reflux disease. Mayo Clinic is the only medical center in Florida and one of two in the Southeast to help study the device. Mayo Clinic in Arizona also offers treatment with the device.
"This is the first new, safe and effective treatment we have to treat reflux disease in 20 years," Dr. Smith says. "The device is simple, elegant and functional, and it provides an opportunity to help a very large number of patients. The only treatment options in the past have been acid-suppressing agents or surgery. Acid-suppressing agents don't directly address the underlying ineffective valve, leaving patients with persistent symptoms; surgery can lead to distressing side effects of bloating and inability to vomit in 20 percent of patients. These side effects occurred rarely with this new device."
Installation of the device is minimally invasive and takes one to two hours. After the procedure, patients stay overnight in the hospital.
Patients who may be helped by the device are those whose acid reflux is chronic with symptoms incompletely controlled by acid-suppressing drugs, Dr. Smith says.
Not all patients in the study fared well with the device. Serious adverse events occurred in six patients, and the device was removed in 4 patients without any significant long-term consequences. Dysphagia - difficulty swallowing - occurred in 68 percent of patients following installation of the device, but this side effect tapered off over time.
The study was recently published online in the New England Journal of Medicine. (ANI)